PRRT2 and cancer: Bryostatin‐1 is a potent inhibitor of mammalian target of rapamycin (mTOR) and competitor of protein kinase C (PKC) regulatory domain, a downstream effector of mTOR that plays a key role in cancer cell metabolism, autophagy, cell cycle progression, and angiogenesis as well 128, 129, 130.